CLAIMS:

1. A method for oral administration via a gastric tube of a solid composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets in a medium in the treatment of gastrointestinal disorders, wherein the pellets are in admixture with one or more pharmaceutically acceptable thickeners and an aqueous carrier and the thickener is capable of forming a viscous medium when dispersed in the aqueous carrier and the formed aqueous suspension is administered through a gastric tube or syringe to a patient in need of such a treatment.

10

- 2. The method according to claim 1, wherein the thickener is selected from the group of starch, xanthan gum, carrageenan, guar gum, locust bean gum, tragacanth, gelatin, pectin and modified cellulose derivatives alone or in any combination.
- 15 3. The method according to claim 1, wherein the thickener is selected from starch and xanthan gum.
 - 4. The method according to claim 1, wherein the composition in addition comprises pharmaceutically acceptable additives selected from flavouring agent, colour agent and sweetening agent.
 - 5. A method for oral administration via a gastric tube of a composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets in a medium in the treatment of gastrointestinal disorders, wherein the medium is a pharmaceutically acceptable viscous aqueous medium in which the pellets are dispersed to form an aqueous suspension and the formed suspension is administered through a gastric tube or syringe to a patient in the need of such treatment.
 - 6. The method according to claim 5, wherein the viscous aqueous medium is selected from yoghurt, sour milk, syrup and aqueous liquids with a similar viscosity.

15

25.

- 7. The method according to claim 5, wherein the viscous aqueous medium is a sugar syrup with a sugar content of at least 63% by weight.
- 8. The method according to any of claims 1 and 5, wherein the viscosity of the formulation after gelation should be 0.005 10 Pa s, as determined at a shear rate of 10 s⁻¹ from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
- 9. The method according to any of claims 1 and 5, wherein the viscosity of the formulation after gelation should be 0.05 5 Pa s, as determined at a shear rate of 10 s⁻¹ from a flow-curve recorded on a rheometer equipped with a plate-plate geometry.
 - 10. The method according to any of claims 1 and 5, wherein the aqueous suspension is administered through tubes with the size CH 5 to CH 10 (CH= Cherrier).
 - 11. The method according to any of claims 1 and 5, wherein the aqueous suspension is administered through tubes with the size CH10 to CH20 (CH= Cherrier).
 - 12. The method according to any of claims 1 and 5, wherein the proton pump inhibitor compound is selected from the group of compounds known under the generic names omeprazole, lansoprazole, pantoprazole, rabeprazole, tenatoprazole and esomeprazole or a pharmaceutically acceptable salt thereof.
 - 13. The method according to any of claims 1 5, wherein the amount of administered active substance is 1 100 mg.
 - 14. The method according to claim 1, wherein the aqueous carrier is selected from the group of water, fruit juice, syrup and dairy products.

- 15. The method according to any of claims 1 -5, wherein the amount of administered viscous medium is approximately 1 35 mL.
- 16. Solid composition comprising a proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, wherein the pellets are in admixture with one or more thickeners capable of forming a viscous medium when dispersed in an aqueous carrier.
- 17. A composition according to claim 16, wherein the enteric coated pellets are spherical and have a size of less than 1 mm.
 - 18. A composition according to claim 16, wherein the enteric coated pellets are spherical and have a size of less than 0.5 mm.
- 19. Use of a thickener in the preparation of a composition for oral administration via a gastric tube in the manufacturing of a medicant for the treatment of gastrointestinal disorders wherein the composition comprises a proton pump inhibitor in the form of a multiple of enteric coating layered pellets, one or more thickeners, and an aqueous carrier, and the thickener is capable of forming a viscous medium when dispersed in the aqueous carrier.
 - 20. Use of a viscous medium in the preparation of a composition for oral administration via a gastric tube in the manufacturing of a medicant for the treatment of gastrointestinal disorders wherein the composition comprises a proton pump inhibitor in the form of a multiple of enteric coating layered pellets and a viscous aqueous medium, and the pellets are dispersed in the viscous medium to an aqueous suspension.